Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients
Sponsored by Pherecydes Pharma
About this trial
Last updated 10 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Started 10 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Man or woman
- Adult Informed consent obtained from patient or next of kin
- In-hospital patient treated for burn wounds in a burn unit
- Burn wound (grafted or not) or graft harvesting area, presenting local signs of infection defined by SFETB criteria:
- Burn wounds with a microbiologically documented infection, as defined by positive surface swab, due to Escherichia coli or Pseudomonas aeruginosa whatever their resistance profile
- Treated by povidone-iodine
Exclusion Criteria
- Pregnant or breastfeeding woman
- Intercurrent condition requiring a treatment which may interfere with analysis results: such as high dose of chronic corticotherapy, immunosuppressive medication, oncologic chemotherapy
- Patient included in an interventional research protocol with therapeutic intervention still ongoing upon inclusion time or having participated into anti-infective drug trials during the previous month.
- Patient considered as part of a vulnerable population
- Patient for whom treatment limitation or withdrawal during study period is considered
- Allergy to Silver Sulfadiazine